ASTech

Founded in 2005, ASTech leveraged its pharmaceutical ingredient development know-how to enter the organic UV filter raw material business in 2015. Its core product is 'Uvimax DHHB,' a UVA-blocking raw material that the company was the first in Korea to localize, and it still accounts for the majority of revenue.

The company also offers other UVA/UVB filter materials including TDSA, BEMT, and EHT. GL Research has described ASTech as Korea's leading organic UV filter raw material specialist with the country's largest UV filter production capacity.

Its customer base is concentrated among a small number of large global cosmetics and chemical companies; the relationship with Netherlands-based DSM is close enough that a DSM affiliate, Firmenich Trading Corporation, made a KRW 16.5 billion equity investment in the company.

On the other hand, a former key customer, a German chemical company referred to in disclosures as 'Company A,' ended its contract in 2024, leaving a gap in the revenue base.

Production is concentrated at the Janghang National Eco-Industrial Complex in Seocheon County, South Chungcheong Province, where the company operates its first plant and has been building a second.

Its technological barrier as the sole domestic producer capable of mass-producing DHHB, backed by multiple process patents, is a key competitive variable. Because the business model centers on B2B raw material supply, changes in order volume from a handful of large customers translate directly into earnings swings.

Consolidated revenue in 2025 fell more than 42% to KRW 24.56bn from KRW 42.57bn in 2024, and operating profit swung to a loss of KRW -110mn from KRW 8.70bn (a 20.4% operating margin) in 2024.

Net profit attributable to owners, however, stayed positive at KRW 2.15bn despite the operating loss, suggesting non-operating items drove the bottom line.

On a quarterly basis, Q2 2025 was relatively solid with revenue of KRW 7.74bn and operating profit of KRW 593mn, but Q3 revenue collapsed to KRW 4.54bn with operating profit narrowing to roughly KRW 14mn.

Q4 2025 saw revenue of KRW 6.08bn alongside an operating loss of KRW -1.73bn, and losses deepened further in Q1 2026 (revenue KRW 4.59bn, operating loss KRW -1.73bn) and Q2 2026 (revenue KRW 4.26bn, operating loss KRW -4.89bn).

As a result, cumulative net loss attributable to owners over the trailing four quarters (Q3 2025-Q2 2026) reached KRW -6.69bn. Compared with the double-digit margin levels of 2023 (revenue KRW 47.34bn, operating margin 19.4%) and 2024, the recent quarterly profit structure has clearly deteriorated.

Operating cash flow fell sharply to KRW 2.89bn in 2025 from KRW 12.43bn in 2024, and the debt ratio climbed from 58.5% (2024) to 83.2% (2025), reflecting increased borrowing tied to the capacity expansion.

It is also worth noting that in 2022, prior to listing, equity stood at only KRW 3.83bn, and the capital base expanded substantially following the IPO.

The global UV-blocking materials market was previously projected by Research and Markets to grow at a 7.5% compound annual rate, from USD 11.4bn in 2021 to USD 17.6bn by 2027.

Rising sun exposure linked to climate change and the growth of the global cosmetics industry, including K-beauty, underpin demand for these raw materials.

UV filter materials are broadly divided into organic and inorganic types, and ASTech focuses on the organic category, which offers advantages in sensory feel and formulation flexibility.

However, final demand in this market is concentrated among a handful of large global chemical companies such as DSM, leaving raw material suppliers exposed to shifts in a few customers' purchasing policies.

The earnings weakness ASTech experienced in 2024-2025 can be viewed as a realization of this customer-concentration risk.

On the competitive front, the company retains its technical position as the sole domestic producer capable of mass-producing DHHB, though the alternative-material and formulation efforts of large overseas chemical companies also warrant monitoring.

In terms of the industry cycle, the company currently sits in a capacity-expansion phase triggered by the completion of its second plant, and whether actual demand recovers along with new customer wins will be the next point to watch.

Company management stated in early 2025 that it expected a full earnings recovery in 2026, but actual results in the first two quarters of 2026 showed operating losses widening instead.

On the production side, the physical foundation for expansion was put in place when the second plant at the Janghang National Eco-Industrial Complex in Seocheon held its completion ceremony on May 20, 2026.

Under an investment agreement with Seocheon County, the company is pursuing roughly KRW 90 billion in facility investment and 40 new hires through 2027, with capacity plans calling for a staged increase from the existing 1,200 tons to several thousand tons over the medium to long term.

GL Research noted in a report dated November 18, 2025 that the company had passed its earnings trough in the third quarter and entered a turnaround phase, though this assessment predates the loss widening seen in the first two quarters of 2026 and diverges from the subsequent trend.

The new production lines are reportedly designed to flexibly produce next-generation UV filters such as DBT and DMTS alongside DHHB on multi-purpose lines, making product diversification and customer-base expansion a key variable for future growth.

That said, the early stage of second-plant operation may first bring higher depreciation and fixed-cost burdens, making it difficult to pinpoint the timing of a profit recovery until an actual revenue rebound is confirmed.